KOIKE MASAMICHI,SPITALNY GEORGE L.,WHEELER ALISTAIR,WHITE BARBARA
申请号：
NZ59927808
公开号：
NZ599278A
申请日:
2008.05.14
申请国别(地区):
NZ
年份:
2013
代理人:
摘要：
NZ 599278 Disclosed is the use of a monoclonal, chimeric, humanised or human antibody that binds IL-5R in the manufacture of a medicament for treating or preventing an eosinophil mediated disease or disorder in a human subject, wherein said antibody is parenterally administered to said subject between about 0.01 to about 0.25 mg/kg, and wherein said antibody comprises an immunoglobulin Fc region comprising no fucose, and wherein the administration of the antibody reduces the number of peripheral blood eosinophils from the human subjects circulation below the limit of detection and the circulating eosinophil count level remains below detection for at least about 28 days after dosing of the antibody.
